Furthermore, they tested the therapeutic potential of CjCas9 by targeting the Vegfa or Hif1a genes, genes associated with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) in mice. This evidence concerns the gene VEGFA and age-related macular degeneration.